2013 Q4 Form 10-Q Financial Statement
#000119312513438277 Filed on November 12, 2013
Income Statement
Concept | 2013 Q4 | 2013 Q3 | 2012 Q3 |
---|---|---|---|
Revenue | |||
YoY Change | |||
Cost Of Revenue | |||
YoY Change | |||
Gross Profit | |||
YoY Change | |||
Gross Profit Margin | |||
Selling, General & Admin | $2.980M | $2.260M | $8.090M |
YoY Change | -78.2% | -72.06% | 2351.52% |
% of Gross Profit | |||
Research & Development | $13.01M | $12.07M | $17.78M |
YoY Change | 57.13% | -32.12% | |
% of Gross Profit | |||
Depreciation & Amortization | $120.0K | $110.0K | $70.00K |
YoY Change | 50.0% | 57.14% | |
% of Gross Profit | |||
Operating Expenses | $15.99M | $14.33M | $25.87M |
YoY Change | -27.15% | -44.61% | 7647.94% |
Operating Profit | -$14.33M | -$25.87M | |
YoY Change | -44.61% | 7647.94% | |
Interest Expense | $40.00K | $10.00K | $10.00K |
YoY Change | 0.0% | 0.0% | |
% of Operating Profit | |||
Other Income/Expense, Net | $0.00 | $48.00K | $14.00K |
YoY Change | 242.86% | -203.7% | |
Pretax Income | -$15.95M | -$14.28M | -$25.86M |
YoY Change | -27.2% | -44.78% | 7288.57% |
Income Tax | $0.00 | $0.00 | $0.00 |
% Of Pretax Income | |||
Net Earnings | -$15.95M | -$14.28M | -$25.86M |
YoY Change | -27.23% | -44.77% | 7342.85% |
Net Earnings / Revenue | |||
Basic Earnings Per Share | |||
Diluted Earnings Per Share | -$554.8K | -$497.9K | -$1.290M |
COMMON SHARES | |||
Basic Shares Outstanding | 28.69M shares | 28.68M shares | 20.04M shares |
Diluted Shares Outstanding |
Balance Sheet
Concept | 2013 Q4 | 2013 Q3 | 2012 Q3 |
---|---|---|---|
SHORT-TERM ASSETS | |||
Cash & Short-Term Investments | $83.90M | $95.60M | $33.30M |
YoY Change | -38.94% | 187.09% | |
Cash & Equivalents | $43.04M | $51.26M | $33.35M |
Short-Term Investments | $40.90M | $44.40M | |
Other Short-Term Assets | $2.600M | $3.600M | $800.0K |
YoY Change | 160.0% | 350.0% | |
Inventory | |||
Prepaid Expenses | |||
Receivables | $9.800M | $11.30M | |
Other Receivables | $9.813M | $11.29M | |
Total Short-Term Assets | $96.40M | $110.6M | $34.12M |
YoY Change | -35.29% | 224.11% | |
LONG-TERM ASSETS | |||
Property, Plant & Equipment | $1.684M | $1.619M | $1.169M |
YoY Change | 13.86% | 38.5% | |
Goodwill | |||
YoY Change | |||
Intangibles | |||
YoY Change | |||
Long-Term Investments | |||
YoY Change | |||
Other Assets | $6.300M | $2.900M | $1.200M |
YoY Change | 425.0% | 141.67% | |
Total Long-Term Assets | $7.978M | $4.533M | $2.381M |
YoY Change | 192.56% | 90.4% | |
TOTAL ASSETS | |||
Total Short-Term Assets | $96.40M | $110.6M | $34.12M |
Total Long-Term Assets | $7.978M | $4.533M | $2.381M |
Total Assets | $104.4M | $115.1M | $36.50M |
YoY Change | -31.2% | 215.39% | |
SHORT-TERM LIABILITIES | |||
YoY Change | |||
Accounts Payable | $10.69M | $9.730M | $1.018M |
YoY Change | 2118.26% | 855.75% | 409.03% |
Accrued Expenses | $8.579M | $9.496M | $25.64M |
YoY Change | -59.57% | -62.97% | |
Deferred Revenue | |||
YoY Change | |||
Short-Term Debt | $0.00 | $0.00 | $0.00 |
YoY Change | -100.0% | ||
Long-Term Debt Due | |||
YoY Change | |||
Total Short-Term Liabilities | $19.27M | $19.23M | $26.66M |
YoY Change | -11.2% | -27.88% | 6564.98% |
LONG-TERM LIABILITIES | |||
Long-Term Debt | $0.00 | $0.00 | $0.00 |
YoY Change | |||
Other Long-Term Liabilities | $1.100M | $1.100M | $800.0K |
YoY Change | 0.0% | 37.5% | |
Total Long-Term Liabilities | $1.100M | $1.100M | $800.0K |
YoY Change | 0.0% | 37.5% | |
TOTAL LIABILITIES | |||
Total Short-Term Liabilities | $19.27M | $19.23M | $26.66M |
Total Long-Term Liabilities | $1.100M | $1.100M | $800.0K |
Total Liabilities | $20.39M | $20.35M | $27.49M |
YoY Change | -10.54% | -25.99% | 6773.68% |
SHAREHOLDERS EQUITY | |||
Retained Earnings | -$139.3M | ||
YoY Change | |||
Common Stock | $223.2M | $218.1M | $71.68M |
YoY Change | 4.56% | 204.22% | |
Preferred Stock | |||
YoY Change | |||
Treasury Stock (at cost) | |||
YoY Change | |||
Treasury Stock Shares | |||
Shareholders Equity | $83.99M | $94.76M | $9.003M |
YoY Change | |||
Total Liabilities & Shareholders Equity | $104.4M | $115.1M | $36.50M |
YoY Change | -31.2% | 215.39% |
Cashflow Statement
Concept | 2013 Q4 | 2013 Q3 | 2012 Q3 |
---|---|---|---|
OPERATING ACTIVITIES | |||
Net Income | -$15.95M | -$14.28M | -$25.86M |
YoY Change | -27.23% | -44.77% | 7342.85% |
Depreciation, Depletion And Amortization | $120.0K | $110.0K | $70.00K |
YoY Change | 50.0% | 57.14% | |
Cash From Operating Activities | -$13.58M | -$12.00M | -$7.640M |
YoY Change | -45.26% | 57.07% | 5357.14% |
INVESTING ACTIVITIES | |||
Capital Expenditures | -$190.0K | -$80.00K | -$10.00K |
YoY Change | -51.28% | 700.0% | |
Acquisitions | |||
YoY Change | |||
Other Investing Activities | $3.490M | $2.300M | $0.00 |
YoY Change | |||
Cash From Investing Activities | $3.290M | $2.230M | -$10.00K |
YoY Change | -943.59% | -22400.0% | |
FINANCING ACTIVITIES | |||
Cash Dividend Paid | |||
YoY Change | |||
Common Stock Issuance & Retirement, Net | |||
YoY Change | |||
Debt Paid & Issued, Net | |||
YoY Change | |||
Cash From Financing Activities | 2.070M | 150.0K | 0.000 |
YoY Change | -98.4% | -100.0% | |
NET CHANGE | |||
Cash From Operating Activities | -13.58M | -12.00M | -7.640M |
Cash From Investing Activities | 3.290M | 2.230M | -10.00K |
Cash From Financing Activities | 2.070M | 150.0K | 0.000 |
Net Change In Cash | -8.220M | -12.00M | -7.650M |
YoY Change | -107.9% | 56.86% | -25600.0% |
FREE CASH FLOW | |||
Cash From Operating Activities | -$13.58M | -$12.00M | -$7.640M |
Capital Expenditures | -$190.0K | -$80.00K | -$10.00K |
Free Cash Flow | -$13.39M | -$11.92M | -$7.630M |
YoY Change | -45.17% | 56.23% | 5350.0% |
Facts In Submission
Frame | Concept Type | Concept / XBRL Key | Value | Unit |
---|---|---|---|---|
CY2013Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
757686 | shares |
CY2013Q3 | us-gaap |
Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
|
2116250 | shares |
CY2013Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
14.76 | |
CY2013Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
2373309 | shares |
CY2013Q3 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
|
1615623 | shares |
CY2013Q3 | us-gaap |
Share Price
SharePrice
|
16.00 | |
CY2013Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
4.82 | |
CY2011Q4 | us-gaap |
Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
|
6900000 | |
CY2011Q4 | pbyi |
Class Of Warrant Or Right Term
ClassOfWarrantOrRightTerm
|
P10Y | |
CY2013Q4 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
28689304 | shares |
CY2011Q3 | pbyi |
Merger Stock Conversion Ratio
MergerStockConversionRatio
|
1 | pure |
CY2012Q3 | us-gaap |
Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
|
13800000 | |
CY2012Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
33347000 | |
CY2013Q3 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
28689304 | shares |
CY2013Q3 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | shares |
CY2013Q3 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
CY2013Q3 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
28689304 | shares |
CY2013Q3 | us-gaap |
Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
|
1213000 | |
CY2013Q3 | us-gaap |
Other Receivables Net Current
OtherReceivablesNetCurrent
|
11294000 | |
CY2013Q3 | us-gaap |
Deposits Assets Noncurrent
DepositsAssetsNoncurrent
|
1701000 | |
CY2013Q3 | us-gaap |
Leasehold Improvements Gross
LeaseholdImprovementsGross
|
913000 | |
CY2013Q3 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
2193000 | |
CY2013Q3 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
294000 | |
CY2013Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
94760000 | |
CY2013Q3 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
218070000 | |
CY2013Q3 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
9496000 | |
CY2013Q3 | us-gaap |
Liabilities
Liabilities
|
20349000 | |
CY2013Q3 | us-gaap |
Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
|
1123000 | |
CY2013Q3 | us-gaap |
Common Stock Value
CommonStockValue
|
3000 | |
CY2013Q3 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
115109000 | |
CY2013Q3 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
19226000 | |
CY2013Q3 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-8000 | |
CY2013Q3 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
1866000 | |
CY2013Q3 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
574000 | |
CY2013Q3 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
78000 | |
CY2013Q3 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
9730000 | |
CY2013Q3 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
1619000 | |
CY2013Q3 | us-gaap |
Assets
Assets
|
115109000 | |
CY2013Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
51261000 | |
CY2013Q3 | us-gaap |
Furniture And Fixtures Gross
FurnitureAndFixturesGross
|
513000 | |
CY2013Q3 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
|
37007000 | |
CY2013Q3 | us-gaap |
Cash Uninsured Amount
CashUninsuredAmount
|
52600000 | |
CY2013Q3 | us-gaap |
Development Stage Enterprise Deficit Accumulated During Development Stage
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage
|
123305000 | |
CY2013Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
90329000 | |
CY2013Q3 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
|
19000000 | |
CY2013Q3 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
3644000 | |
CY2013Q3 | us-gaap |
Marketable Securities Current
MarketableSecuritiesCurrent
|
44377000 | |
CY2013Q3 | us-gaap |
Assets Current
AssetsCurrent
|
110576000 | |
CY2013Q3 | pbyi |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term3
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3
|
P8Y9M18D | |
CY2013Q3 | pbyi |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Intrinsic Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedIntrinsicValue
|
64490000 | |
CY2013Q3 | pbyi |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Exercise Price
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice
|
19.42 | |
CY2013Q3 | pbyi |
Accrued Development Costs
AccruedDevelopmentCosts
|
5887000 | |
CY2013Q3 | pbyi |
Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
|
1371000 | |
CY2011Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
54372000 | |
CY2011Q4 | us-gaap |
Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
|
7600000 | |
CY2011Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
53382000 | |
CY2012Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
28676666 | shares |
CY2012Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
8.93 | |
CY2012Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
1906334 | shares |
CY2012Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | shares |
CY2012Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
CY2012Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
28676666 | shares |
CY2012Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
21701000 | |
CY2012Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
787000 | |
CY2012Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
276000 | |
CY2012Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
76000 | |
CY2012Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
482000 | |
CY2012Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
121000 | |
CY2012Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
128909000 | |
CY2012Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
213498000 | |
CY2012Q4 | us-gaap |
Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
|
25800000 | |
CY2012Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
21219000 | |
CY2012Q4 | us-gaap |
Liabilities
Liabilities
|
22790000 | |
CY2012Q4 | us-gaap |
Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
|
1089000 | |
CY2012Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
3000 | |
CY2012Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
151699000 | |
CY2012Q4 | us-gaap |
Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
|
1212000 | |
CY2012Q4 | us-gaap |
Other Receivables Net Current
OtherReceivablesNetCurrent
|
10612000 | |
us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-47791000 | ||
CY2012Q4 | us-gaap |
Furniture And Fixtures Gross
FurnitureAndFixturesGross
|
276000 | |
CY2012Q4 | us-gaap |
Development Stage Enterprise Deficit Accumulated During Development Stage
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage
|
84592000 | |
CY2012Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
18966000 | |
CY2012Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
952000 | |
CY2012Q4 | us-gaap |
Deposits Assets Noncurrent
DepositsAssetsNoncurrent
|
36000 | |
CY2012Q4 | us-gaap |
Leasehold Improvements Gross
LeaseholdImprovementsGross
|
910000 | |
CY2012Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
1755000 | |
CY2012Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
1479000 | |
CY2012Q4 | us-gaap |
Assets
Assets
|
151699000 | |
CY2012Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
137408000 | |
CY2012Q4 | us-gaap |
Assets Current
AssetsCurrent
|
148972000 | |
CY2012Q4 | pbyi |
Accrued Development Costs
AccruedDevelopmentCosts
|
19846000 | |
CY2012Q4 | pbyi |
Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
|
389000 | |
us-gaap |
Equity Issuance Per Share Amount
EquityIssuancePerShareAmount
|
0.0001 | ||
us-gaap |
Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
|
7000 | ||
us-gaap |
Net Income Loss
NetIncomeLoss
|
-7000 | ||
us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-87312000 | ||
us-gaap |
Payments For Capital Improvements
PaymentsForCapitalImprovements
|
913000 | ||
us-gaap |
Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
|
1213000 | ||
us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
-8000 | ||
us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
230000 | ||
us-gaap |
Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
|
11294000 | ||
us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
44385000 | ||
us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-123305000 | ||
us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-77000 | ||
us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-123313000 | ||
us-gaap |
Other Noncash Income Expense
OtherNoncashIncomeExpense
|
-903000 | ||
us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-123458000 | ||
us-gaap |
Payments For Proceeds From Productive Assets
PaymentsForProceedsFromProductiveAssets
|
1280000 | ||
us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
153000 | ||
us-gaap |
Net Income Loss
NetIncomeLoss
|
-123305000 | ||
us-gaap |
Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
|
150000 | ||
us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
40956000 | ||
us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
186364000 | ||
us-gaap |
Share Based Compensation
ShareBasedCompensation
|
5901000 | ||
us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
574000 | ||
us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
51261000 | ||
us-gaap |
Operating Expenses
OperatingExpenses
|
123458000 | ||
us-gaap |
Proceeds From Contributed Capital
ProceedsFromContributedCapital
|
68000 | ||
us-gaap |
Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
|
25808000 | ||
us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
9496000 | ||
us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
9730000 | ||
us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
185955000 | ||
us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
191000 | ||
us-gaap |
Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
|
150000 | ||
us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
82502000 | ||
dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001401667 | ||
dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | ||
pbyi |
Increase Decrease In Prepaid Expense And Other Assets
IncreaseDecreaseInPrepaidExpenseAndOtherAssets
|
5345000 | ||
pbyi |
Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
|
220000 | ||
dei |
Trading Symbol
TradingSymbol
|
PBYI | ||
dei |
Entity Registrant Name
EntityRegistrantName
|
PUMA BIOTECHNOLOGY, INC. | ||
dei |
Amendment Flag
AmendmentFlag
|
false | ||
dei |
Entity Filer Category
EntityFilerCategory
|
Accelerated Filer | ||
dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2013 | ||
dei |
Document Type
DocumentType
|
10-Q | ||
dei |
Document Period End Date
DocumentPeriodEndDate
|
2013-09-30 | ||
dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q3 | ||
us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
11.60 | ||
us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P9Y4M24D | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
|
499475 | shares | |
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
|
12638 | shares | |
us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
36.80 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue
|
|||
us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
28678439 | shares | |
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
25.95 | ||
us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-86147000 | ||
us-gaap |
Operating Expenses
OperatingExpenses
|
38844000 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
|||
us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
|
P2Y4M24D | ||
us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-41469000 | ||
us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<div> <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> <b>Concentration of Risk:</b></p> <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> Financial instruments, which potentially subject the Company to concentrations of credit risk, principally consist of cash and cash equivalents. The Company’s cash and cash equivalents in excess of the Federal Deposit Insurance Corporation and the Securities Investor Protection Corporation insured limits at September 30, 2013, were approximately $52.6 million. The Company does not believe it is exposed to any significant credit risk.</p> </div> | ||
us-gaap |
Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
|
<div> <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> <b>Reclassifications:</b></p> <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> Certain amounts for 2012 have been reclassified to conform to the current year’s presentation.</p> </div> | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
19862 | shares | |
us-gaap |
Use Of Estimates
UseOfEstimates
|
<div> <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> <b>Use of Estimates:</b></p> <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet and reported amounts of expenses for the period presented. Accordingly, actual results could differ from those estimates. Significant estimates include the cost of services provided by consultants who manage clinical trials and conduct research and clinical trials on behalf of the Company that are billed on a delayed basis. As the actual costs become known, the Company adjusts its estimated cost in that period. The value of stock-based compensation includes estimates based on future events which are difficult to predict. It is at least reasonably possible that a change in the estimates will occur in the near term.</p> </div> | ||
us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-1.35 | ||
us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
11.60 | ||
us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
|
P8Y4M24D | ||
us-gaap |
Payments For Capital Improvements
PaymentsForCapitalImprovements
|
3000 | ||
us-gaap |
Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
|
1000 | ||
us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
-8000 | ||
us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
146000 | ||
us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
128000 | ||
us-gaap |
Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
|
682000 | ||
us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
44385000 | ||
us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-38713000 | ||
us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
3000 | ||
us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-38721000 | ||
us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-38844000 | ||
us-gaap |
Payments For Proceeds From Productive Assets
PaymentsForProceedsFromProductiveAssets
|
435000 | ||
us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
131000 | ||
us-gaap |
Net Income Loss
NetIncomeLoss
|
-38713000 | ||
us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
4426000 | ||
us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
6804000 | ||
us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
146000 | ||
us-gaap |
Share Based Compensation
ShareBasedCompensation
|
4426000 | ||
us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
298000 | ||
us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
-11723000 | ||
us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
9248000 | ||
us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
32040000 | ||
us-gaap |
Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
|
200600 | ||
us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
146000 | ||
us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
4426000 | ||
us-gaap |
Cost Of Reimbursable Expense
CostOfReimbursableExpense
|
13100000 | ||
us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-44824000 | ||
pbyi |
Marketable Securities Maturity Period
MarketableSecuritiesMaturityPeriod
|
P4M | ||
pbyi |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm
|
P9Y | ||
pbyi |
Share Based Compensation Effect On Earnings Per Share Basic And Diluted
ShareBasedCompensationEffectOnEarningsPerShareBasicAndDiluted
|
0.15 | ||
pbyi |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue
|
|||
pbyi |
Increase Decrease In Prepaid Expense And Other Assets
IncreaseDecreaseInPrepaidExpenseAndOtherAssets
|
4357000 | ||
pbyi |
Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
|
34000 | ||
pbyi |
License Agreement Number Of Days To Review Invoice And Supporting Documentation
LicenseAgreementNumberOfDaysToReviewInvoiceAndSupportingDocumentation
|
P60D | ||
us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
20040000 | shares | |
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
4.63 | ||
us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-19203000 | ||
us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
1422500 | shares | |
us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-2.62 | ||
us-gaap |
Payments For Capital Improvements
PaymentsForCapitalImprovements
|
236000 | ||
us-gaap |
Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
|
159000 | ||
us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
63000 | ||
us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-52440000 | ||
us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-52440000 | ||
us-gaap |
Other Noncash Income Expense
OtherNoncashIncomeExpense
|
-237000 | ||
us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-52503000 | ||
us-gaap |
Payments For Proceeds From Productive Assets
PaymentsForProceedsFromProductiveAssets
|
437000 | ||
us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
63000 | ||
us-gaap |
Net Income Loss
NetIncomeLoss
|
-52440000 | ||
us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
11149000 | ||
us-gaap |
Share Based Compensation
ShareBasedCompensation
|
820000 | ||
us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
187000 | ||
us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-20035000 | ||
us-gaap |
Operating Expenses
OperatingExpenses
|
52503000 | ||
us-gaap |
Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
|
6250000 | ||
us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
25142000 | ||
us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
931000 | ||
us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
7070000 | ||
us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-832000 | ||
us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
41354000 | ||
us-gaap |
Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
|
97400 | ||
us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
6200000 | ||
pbyi |
Share Based Compensation Effect On Earnings Per Share Basic And Diluted
ShareBasedCompensationEffectOnEarningsPerShareBasicAndDiluted
|
0.35 | ||
pbyi |
Increase Decrease In Prepaid Expense And Other Assets
IncreaseDecreaseInPrepaidExpenseAndOtherAssets
|
489000 | ||
pbyi |
Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
|
159000 | ||
CY2011Q3 | us-gaap |
Noncash Or Part Noncash Acquisition Noncash Financial Or Equity Instrument Consideration Shares Issued1
NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1
|
18666733 | shares |
CY2011Q3 | us-gaap |
Payments For Merger Related Costs
PaymentsForMergerRelatedCosts
|
40000 | |
CY2011Q3 | us-gaap |
Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
|
40000 | |
CY2011Q3 | pbyi |
Noncash Or Part Noncash Acquisition Noncash Financial Or Equity Instrument Shares Received
NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentSharesReceived
|
18666733 | shares |
CY2011Q4 | invest |
Investment Warrants Expiration Date
InvestmentWarrantsExpirationDate
|
2021-10-04 | |
CY2011 | us-gaap |
Equity Issuance Per Share Amount
EquityIssuancePerShareAmount
|
3.75 | |
CY2011 | us-gaap |
Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
|
61000 | |
CY2011 | us-gaap |
Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
|
7586000 | |
CY2011 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-10233000 | |
CY2011 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
67000 | |
CY2011 | us-gaap |
Other Expenses
OtherExpenses
|
80000 | |
CY2011 | pbyi |
Issuance Of Common Stock In Exchange For Convertible Notes Value
IssuanceOfCommonStockInExchangeForConvertibleNotesValue
|
150000 | |
CY2012 | us-gaap |
Equity Issuance Per Share Amount
EquityIssuancePerShareAmount
|
16.00 | |
CY2012 | us-gaap |
Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
|
18222000 | |
CY2012 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
45000 | |
CY2012 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-74352000 | |
CY2012 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
1408000 | |
CY2012Q3 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
20040000 | shares |
CY2012Q3 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
1422500 | shares |
CY2012Q3 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-1.29 | |
CY2012Q3 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
14000 | |
CY2012Q3 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-25859000 | |
CY2012Q3 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-25859000 | |
CY2012Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-25873000 | |
CY2012Q3 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
14000 | |
CY2012Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-25859000 | |
CY2012Q3 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
8094000 | |
CY2012Q3 | us-gaap |
Operating Expenses
OperatingExpenses
|
25873000 | |
CY2012Q3 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
-6226000 | |
CY2012Q3 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
17779000 | |
CY2012Q3 | us-gaap |
Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
|
40800 | |
CY2012Q3 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
6500000 | |
CY2012Q3 | pbyi |
Share Based Compensation Effect On Earnings Per Share Basic And Diluted
ShareBasedCompensationEffectOnEarningsPerShareBasicAndDiluted
|
-0.31 | |
CY2013Q3 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
28682055 | shares |
CY2013Q3 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-12000000 | |
CY2013Q3 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.50 | |
CY2013Q3 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
66000 | |
CY2013Q3 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
9000 | |
CY2013Q3 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-14283000 | |
CY2013Q3 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
39000 | |
CY2013Q3 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-14217000 | |
CY2013Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-14331000 | |
CY2013Q3 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
48000 | |
CY2013Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-14283000 | |
CY2013Q3 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
2263000 | |
CY2013Q3 | us-gaap |
Operating Expenses
OperatingExpenses
|
14331000 | |
CY2013Q3 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
1806000 | |
CY2013Q3 | us-gaap |
Cost Of Reimbursable Expense
CostOfReimbursableExpense
|
3400000 | |
CY2013Q3 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
12068000 | |
CY2013Q3 | us-gaap |
Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
|
97000 | |
CY2013Q3 | pbyi |
Share Based Compensation Effect On Earnings Per Share Basic And Diluted
ShareBasedCompensationEffectOnEarningsPerShareBasicAndDiluted
|
0.06 |